Testing of iPSC derived retinal pigment epithelium to treat macular degeneration

The NIH-funded Regenerative Medicine Innovation Catalyst will: ? Provide in-depth and independent characterization of the source stem cell line and stem cell-derived products being developed, ? Provide a platform for sharing and analysis of clinical trial (if applicable) and cell product characterization data, thereby potentially enabling correlation of stem cell-derived product attributes with clinical outcomes, and ? Create a foundation for enhancing our understanding of clinical outcomes, refining production methods, and informing future RM product development. Importantly, the RMIC will promote transparency and ultimately may contribute to reproducibility and standardization of clinical grade stem cell-derived products.